G. Michael Wall
Senior Director Pharmaceutical Development
business and management
Sound Pharmaceuticals
United States of America
Biography
Dr. Wall is an accomplished leader in specialty pharmaceuticals, best exemplified by his successes while at Alcon Laboratories where he launched their Otolaryngology R&D efforts. Dr. Wall led the development and commercialization of Ciprodex® Otic Suspension for the treatment of acute otitis externa and acute otitis media in patients with tympanostomy tubes which remains the #1 eardrop prescribed by otolaryngologists and pediatricians in the U.S. He also led the development and commercialization of Patanase® Nasal Spray for the treatment of allergic rhinitis in children (including pediatric exclusivity) and adults (#1 intranasal antihistamine prescribed by U.S. pediatricians). Further, he led development for other otic products such as XTORO® and formulation improvements for CIPRO® HC, and significantly contributed to development of ophthalmic products such as AZOPT®, BETOPTIC® S, CILOXAN®, IOPIDINE®, PATADAY®, PATANOL®, TRAVATAN®, VEXOL® and VIGAMOX®. He has directed the conduct of over 40 clinical trials, phase 1-4. Dr. Wall earned his Ph.D. in Medicinal Chemistry from the University of Mississippi School of Pharmacy and has completed Harvard Business School’s Advanced Management Program. (Trademarks are property of their owners.)
Research Interest
BUSINESS AND MANAGEMENT
